On 12 Nov 2026 Baxter International closed at $25.74, +34.9% this year; market cap $13.38bn.
Health Care · Health Care Equipment · NYSE · United States
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
| Market cap | $13.38bn |
| P/E (trailing) | — |
| EPS (TTM) | $-1.39 |
| Beta | 0.67 |
| Dividend | $0.04 |
| Dividend yield | 0.16% |
| Ex-dividend date | 27 Nov 2026 |
| Latest report | 29 Oct 2026 |
| Next earnings | 28 Jan 2027 |
| YTD | +34.9% |
| 1Y | +37.9% |
| 3Y | -6.9% |
| 5Y | -18.6% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $11.24bn | $-957.00m | $323.00m |
| 2024 | $10.64bn | $-649.00m | $559.00m |
| 2023 | $10.36bn | $2.66bn | $1.29bn |
| 2022 | $10.06bn | $-2.43bn | $532.00m |
| 2021 | $12.15bn | $1.28bn | $1.48bn |
We publish no single base value for Baxter International. Our valuation methods put it between $21.58 and $38.73 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.